Administration of NGF directly into the basal forebrain indicates positive effects in AD patients with respect to biomarkers, histology and cognitive functions, and shows no side effects (Eriksdotter‐Jönhagen et al., 2012; Eyjolfsdottir et al., 2016; Ferreira et al., 2015; Karami et al., 2015; Tuszynski et al., 2005; Wahlberg et al., 2012). The gene discussed is NGF; the disease is Alzheimer disease.